A group of researchers, led by Mark Pepys, at University College London has designed and chemically synthesised a new drug, which they have shown to reduce heart tissue damage following a heart attack.

Microsoft Corp. is spinning out some of its software technology to two small European tech ventures, as part of a program to speed development of innovations from its labs.

Fujeribio Diagnostics, Inc., based in Japan, has bought Swedish CanAg Diagnostics, merging two leading biotechnology companies in cancer diagnosis.

A team of researchers at ORNL has come up with the concept of nanofermentation, and, it seems, plans to use this as a trademark.

On May 26, the US Patent Office issued a preliminary ruling on another long-running patent fight. This battle differs from other high-profile clashes as the challenger is taking on not a big corporate entity, but a broad community of IT researchers and academics.

Europabio thinks that Europe is doing a poor job when it comes to investing in biotechnology.

Open source software has broken the stranglehold of proprietary software vendors. Could the Biological Open Source initiative do the same in biotech?

The UK government has created two new Enterprise Capital Funds (ECF) under its £40 million scheme to aid high tech businesses caught in the equity gap.

Researchers from Helsinki University have found a way to fight cancer by chewing gum. The gum contains a substance which breaks down carcinogens in the mouth caused by smoking and drinking.

Secure Access Solutions, a spin-off from the University of Warwick, has developed a new kind of magnifying lens to help the visually impaired type their pin codes into card readers in shops. It is seeking licensees and investors.